ARIAD Chief Executive Officer, Harvey J. Berger, M.D., Recognized as 2013 Ernst & Young Entrepreneur of the Year® in New

  ARIAD Chief Executive Officer, Harvey J. Berger, M.D., Recognized as 2013
  Ernst & Young Entrepreneur of the Year® in New England

Business Wire

CAMBRIDGE, Mass. -- June 28, 2013

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that Harvey J.
Berger, M.D., founder, chairman and chief executive officer of ARIAD, was
named by Ernst & Young as a 2013 Entrepreneur Of The Year for the New England
region. The award recognizes entrepreneurial excellence in ten industry
categories. Dr. Berger was among thirty-two finalists who represented the
region’s top executives across all major industries, and he received his award
in the biotechnology category. The award recognizes outstanding entrepreneurs
at high-growth companies that demonstrate excellence and extraordinary success
in innovation, financial performance, personal commitment to their businesses
and communities, and other areas.

ARIAD Chief Executive Officer, Harvey J. Berger, M.D (Photo: Business Wire)

ARIAD Chief Executive Officer, Harvey J. Berger, M.D (Photo: Business Wire)

“It is an honor to be recognized as an Entrepreneur Of The Year in New England
by Ernst & Young, “stated Dr. Berger. “This award is a testament to the
outstanding work of ARIAD employees in bringing life-transforming medicines to
cancer patients. In the last twenty years, we have remained dedicated to
advancing scientific and medical research and now making our new cancer
medicine, Iclusig^®, available to patients around the world. Our employees
have provided the essential support that has allowed us to position the
company for strong growth and expansion.”

Ernst & Young recognizes Entrepreneur of the Year winners in 25 US regions.
Regional winners go on to compete at the national level. Award winners in
several national categories, as well as the National Entrepreneur Of The Year
Overall Award winner, will be announced at the annual awards gala in Palm
Springs, California, on November 16, 2013.

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and
Lausanne, Switzerland, is an integrated global oncology company focused on
transforming the lives of cancer patients with breakthrough medicines. ARIAD
is working on new medicines to advance the treatment of various forms of
chronic and acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer medicines.
For additional information, visit http://www.ariad.comor follow ARIAD on
Twitter (@ARIADPharm).

About Ernst & Young

Ernst & Young is a global leader in assurance, tax, transaction and advisory
services. Worldwide, our 167,000 people are united by our shared values and an
unwavering commitment to quality. We make a difference by helping our people,
our clients and our wider communities achieve their potential.

For more information, please visit ey.com.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130628005285/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50661676&lang=en

Contact:

ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
Kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com
 
Press spacebar to pause and continue. Press esc to stop.